Specialty Pharmacy

Using genetic testing for women newly diagnosed with breast cancer can decrease the high cost of chemotherapy use in the first year of care.

Top news of the day from across the health care landscape.

Amifampridine (Ruzurgi, Jacobus) is the first treatment approved specifically for pediatric patients 6 to 17 years of age with Lambert-Eaton myasthenic syndrome.

A certain type of DNA rearrangement that is rarely tested for may be a predictor of prognosis in multiple myeloma.

Ado-trastuzumab emtansine (Kadcyla) is currently the only antibody-drug conjugate approved for the treatment of HER2-positive early and metastatic breast cancer.

Matt Farber, MA, Senior Director of Patient Care and Advocacy at Walgreens, talks about the growing role of specialty pharmacies in delivering cancer care.

Top news of the day from across the health care landscape.

Transthyretin amyloid cardiomyopathy is a rare and fatal disease for which there are no previously approved treatments.

Officials with the FDA have approved AstraZeneca’s dapagliflozin, saxagliptin and metformin hydrochloride (Qternmet XR) extended release tablets for adults with type 2 diabetes.

A molecular switch in the skin cells may cause increased susceptibility to autoimmunity in women.

It was during the middle of the night when Suzanne Soliman, PharmD, founder of the Pharmacist Mom Group on Facebook, got the idea for her group page, which has since grown to be one of the most active on the popular social media platform, with more than 2 million posts last year alone.

At the Asembia Specialty Pharmacy Summit 2019, Matt Farber, MA, Senior Director of Patient Care and Advocacy at Walgreens discussed top trends in specialty pharmacy that are likely to continue to impact the industry.

The sNDA was granted Priority Review and accepted under the agency's Real-Time Oncology Review pilot program, which aims to make the review of oncology drugs more efficient by allowing the FDA access to clinical trial data before the information is formally submitted to the agency.

This weekly video program provides our readers with an in-depth review of the latest news, product approvals, FDA rulings, and more. Our Week in Review is a can't miss for the busy pharmacy professional. 

During the featured session at Asembia’s Specialty Pharmacy Summit 2019, “Specialty Industry Outlook: What’s Next,” speakers Adam Fein, PhD, CEO of the Drug Channels Institute; Lisa Gill, managing director of J.P. Morgan Securities; and Doug Long, vice president of industry relations at IQVIA, explored the radical changes that could be on the horizon from potential legislation that would dramatically alter the health care industry.

Matt Farber, MA, Senior Director of Patient Care and Advocacy at Walgreens provided insight into new areas of technology that pharmacists can use to help improve care when treating patients with cancer.

Matt Farber, MA, Senior Director of Patient Care and Advocacy at Walgreens, discussed the role of specialty pharmacists in working to manage the cost burden of cancer care.

Since the growth of specialty pharmacies, genetically acquired bleeding disorders such as von Willebrand disease (VWD) have been among the most common conditions addressed at these practice locations.

At the Asembia Specialty Pharmacy Summit 2019, Scott Gottlieb, MD, 23rd commissioner of the FDA discussed the agency's role in rewriting the modern rules of new regulatory paradigms for a number of recent advancements in medicine.

Patients taking beta interferons for at least 6 months had a reduced mortality risk compared with patients who did not take the drug.

The drug application was granted the FDA’s Priority Review designation, as well as a Tropical Disease Priority Review Voucher under a program intended to encourage development of new drugs and biologics for the prevention and treatment of certain tropical diseases.

Top news of the week from Specialty Pharmacy Times.

Matthew Malachowski, PharmD, BCPS, supervisor of specialty pharmacy services at UAB Health System, discusses opportunities to improve the patient experience.

Most Americans have never heard of hereditary transthyretin amyloidosis (hATTR), which speaks to its very low incidence rate in the population.

The study authors believe that the modification of teriflunomide and the development of new DHODH inhibitors is urgent for drug-resistant epilepsy patients

Partnerships like the UC College of Pharmacy and Walgreens offer opportunities for experience with complex disease states, such as cancer, multiple sclerosis, HIV, and Crohn’s disease, that many students will see after they graduate.

The oncology drug pipeline has experienced rapid growth over the past decade, driven by innovation in cell therapies, immunotherapy, and precision medicine, according to a specialty pipeline update presentation at the Asembia Specialty Pharmacy Summit 2019.

Co-pay accumulator programs are the latest cost management initiative resulting from the constant push and pull between payers, pharmacy benefit managers, and manufacturers to reduce drug spend.

Mouthwash containing diphenhydramine, lidocaine, and antacids found to significantly reduce pain from oral mucositis in patients with head and neck cancer administered chemotherapy.

Treatment for inflammatory bowel disease has the best outcomes when patients partner with their medical teams.